Delhi High Court Permanently Restrains Pharmaceutical Products Manufacturers From Using LOOZOUT Trademark, Imposes Rs. 2 Lakhs Cost
Case: Intas Pharmaceuticals Private Limited V. Intra Life Private Limited & Ors.
Coram: Justice Jyoti Singh
Case No.: CS(COMM) 243/2022
Court Observation: “Defendants No. 2 and 3 have chosen to stay away from the proceedings, despite service and thus there is no justification or reasonable explanation to adopt the infringing mark on the products manufactured by them,”
“Since the suit has been settled qua Defendant No.1 at an early stage of litigation, Plaintiff is entitled to refund of 50% of the Court Fees deposited by it, in accordance with provisions of Section 16A of the Court Fees Act, 1870 read with Section 89 CPC, 1908,”
Previous Posts
Money Decree/Certificate Of Recovery In Favour Of Financial Creditor Gives Fresh Cause Of Action To Initiate CIRP U/s 7 IBC: Supreme Court Download Judgement
Keywords
LOOZOUT Trademark, Pharmaceutical Products
Related Articles
- Delhi High Court Permanently Restrains Retail Store From Selling Any Counterfeit Product Under ‘Hettich’ Trademark & Logo
- ‘Lackadaisical Approach’: Delhi High Court Imposes ₹20K Cost On Centre For Failing To Pay Pension To 96 -Yr-Old Freedom Fighter
- Delhi High Court Restrains Parle From Using ‘For The Bold’ Tagline As Predominant Part Of Advertising ‘B Fizz’ Drink In Suit By PepsiCo

